Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $65.0 million
Deal Type : Series A Financing
HAYA Therapeutics Raises $65M Series A for RNA-Guided Chronic Disease Drugs
Details : The funds will used to advance clinical development of ASO heart failure lead candidate HTX-001, which is being evaluated for the treatment of non-obstructive hypertrophic cardiomyopathy.
Product Name : HTX-001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 08, 2025
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $65.0 million
Deal Type : Series A Financing
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
Details : U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.
Product Name : INS-3001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable